Sibrotuzumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Sibrotuzumab
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target FAP
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
 NYesY (what is this?)  (verify)

Sibrotuzumab is a humanized monoclonal antibody intended for the treatment of cancer. It binds to FAP[1][2]

In 2003 it failed a phase II clinical trial for metastatic colorectal cancer.[3]

References[edit]

  1. ^ Scott, AM; Wiseman, G; Welt, S; Adjei, A; Lee, FT; Hopkins, W; Divgi, CR; Hanson, LH; et al. (2003). "A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer". Clinical Cancer Research. 9 (5): 1639–47. PMID 12738716. 
  2. ^ Kloft, C; Graefe, EU; Tanswell, P; Scott, AM; Hofheinz, R; Amelsberg, A; Karlsson, MO (2004). "Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patients". Investigational new drugs. 22 (1): 39–52. PMID 14707493. doi:10.1023/B:DRUG.0000006173.72210.1c. 
  3. ^ Hofheinz, RD; al-Batran, SE; Hartmann, F; Hartung, G; Jäger, D; Renner, C; Tanswell, P; Kunz, U; Amelsberg, A; Kuthan, H; Stehle, G. "Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer". Onkologie. 26: 44–8. PMID 12624517. doi:10.1159/000069863.